Evidence Hub

Managing Erythromelalgia-Associated Pain with Suzetrigine: A Case Report

Hoang D, Hubbell J, Verbeek T

Pain medicine case reports, 2026

Abstract

BACKGROUND: Erythromelalgia is a rare, debilitating chronic condition characterized by erythema, warmth, and recurrent burning pain typically in the feet. Despite numerous treatment options, management of erythromelalgia can be challenging. Sodium channel blockers are offered as treatment options for erythromelalgia; however, they are often nonselective, limiting their utility. Suzetrigine is a novel, selective Nav1.8 sodium channel inhibitor that appears to have promising antinociceptive potential.

CASE REPORT: Our clinical vignette describes the case of a 23-year-old woman with worsening burning pain in her bilateral feet and ankles, diagnosed as erythromelalgia. Various interventions were trialed without adequate relief, including nonpharmacological management, aspirin, lumbar sympathetic block, and various systemic medications. Suzetrigine was ultimately tried with significant pain relief, making this the first described case of suzetrigine alleviating erythromelalgia-associated pain.

CONCLUSIONS: Overall, our highlights suzetrigine's potentially wide applicability in various pain conditions, although additional clinical trials are still required to clarify the full extent.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free